Sarepta Therapeutics | SRPT - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Capricor Therapeutics USD 1.92M 446.47K 2025-12
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Insmed USD 247.26M 34.78M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Moderna USD 173M 135M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03